For years, the most effective weight-loss medicines meant a weekly shot. That changed when the FDA approved two daily pills: the Wegovy pill (oral semaglutide) in December 2025 and Lilly’s Foundayo (orforglipron) in April 2026. They look similar on the pharmacy shelf but work and are taken quite differently. Here’s how they compare.
Key takeaways
- The Wegovy pill contains semaglutide, a peptide. Foundayo contains orforglipron, a small molecule that activates the same GLP-1 receptor but is not a peptide.
- The Wegovy pill must be taken on an empty stomach with a small sip of water, followed by a 30-minute wait. Foundayo can be taken any time, with or without food.
- In their main trials, the Wegovy pill 25 mg produced about 13.6% average weight loss at 64 weeks; Foundayo’s top dose produced about 11.2% at 72 weeks (about 12.4% among people who stayed on treatment).
- Both cost less out of pocket than most injectables in 2026, but prices change often.
- Weekly injections such as Zepbound and Wegovy still produce more average weight loss.
Side-by-side comparison
| Wegovy pill | Foundayo | |
|---|---|---|
| Active ingredient | Semaglutide (peptide) | Orforglipron (non-peptide small molecule) |
| Maker | Novo Nordisk | Eli Lilly |
| FDA approval | December 2025 | April 1, 2026 |
| How often | Once daily | Once daily |
| Food rules | Empty stomach, up to 4 oz water, wait 30 minutes before eating, drinking or other pills | None. With or without food |
| Main trial | OASIS 4: 13.6% vs 2.2% placebo at 64 weeks | ATTAIN-1: 11.2% vs 2.1% placebo at 72 weeks |
| Maintenance dose | 25 mg daily | Up to 17.2 mg daily |
| Typical self-pay range (2026) | About $149 to $299 a month, depending on dose | About $149 to $349 a month, depending on dose |
Prices are manufacturer self-pay offers reported in 2026 and can change at any time. Insurance coverage varies by plan.
Why one pill is a peptide and the other isn’t
Peptides like semaglutide are normally destroyed by stomach acid and enzymes. The Wegovy pill gets around this with an absorption enhancer called SNAC, which briefly protects the drug and helps it cross the stomach lining. That system only works well on an empty stomach, which is why the dosing rules are strict, and why only a small fraction of each tablet is absorbed.
Orforglipron was designed from scratch as a small molecule that fits the GLP-1 receptor. It survives digestion and is absorbed normally, so food doesn’t matter. Because it’s processed by the liver enzyme CYP3A4, it has more potential drug interactions than semaglutide. For background on what makes something a peptide, see what are peptides.
Dose schedules (from the FDA labels)
Wegovy pill
| Days | Daily dose |
|---|---|
| 1 to 30 | 1.5 mg |
| 31 to 60 | 4 mg |
| 61 to 90 | 9 mg |
| 91 onward | 25 mg |
Foundayo
| Step | Daily dose |
|---|---|
| Start | 0.8 mg |
| After at least 30 days | 2.5 mg |
| After at least 30 more days | 5.5 mg |
| Further steps, at least 30 days apart, if needed | 9 mg, 14.5 mg, then 17.2 mg (maximum) |
Foundayo’s trial used capsule doses labeled 6, 12 and 36 mg, which correspond to the approved tablet strengths of 5.5, 9 and 17.2 mg. So you may see “36 mg” in news coverage of the trial.
Weight-loss results in more detail
- Foundayo (ATTAIN-1): 3,127 adults without diabetes. Average loss at 72 weeks was 7.5%, 8.4% and 11.2% for the 5.5, 9 and 17.2 mg doses, versus 2.1% on placebo. At the top dose, 54.6% lost at least 10% of their weight.
- Wegovy pill (OASIS 4): 307 adults without diabetes. Average loss at 64 weeks was 13.6% versus 2.2% on placebo.
The trials differed in size and length, so the gap between the two pills is not precise. For comparison, injectable semaglutide 2.4 mg averages about 15%, and tirzepatide about 20 to 22%. See our weight-loss rankings.
Side effects
Both pills have the same kind of side effects as GLP-1 injections: nausea, diarrhea, vomiting and constipation, mostly while the dose is rising. In ATTAIN-1, nausea affected about 29 to 36% of people on Foundayo versus 10% on placebo, and 3.5 to 7% stopped because of GI effects. In OASIS 4, GI events were reported by 74% on the Wegovy pill versus 42% on placebo, mostly mild to moderate. The same class warnings apply, including pancreatitis, gallbladder disease and the thyroid tumor boxed warning. More detail in our GLP-1 side effects guide.
Drug interactions to know
- Wegovy pill: other oral medicines must wait at least 30 minutes after the tablet. Because it slows stomach emptying, it may affect absorption of drugs such as levothyroxine; your prescriber may monitor levels.
- Foundayo: the label says to avoid strong CYP3A4 inducers, and to avoid strong CYP3A4 inhibitors that also block OATP1B (such as ritonavir) or cap the dose at 9 mg if they must be used together. Always give your pharmacist a full medication list.
Pill or injection: which fits?
- A pill may suit people who dislike needles, travel often, or want a lower-cost entry point.
- Foundayo may suit people who can’t manage the Wegovy pill’s empty-stomach routine.
- An injection may suit people who need the largest possible weight loss or prefer once-weekly dosing.
Your clinician will also weigh other conditions, other medicines and insurance coverage.
Frequently asked questions
Is Foundayo a peptide?
No. Orforglipron is a small-molecule drug that activates the GLP-1 receptor. The Wegovy pill contains semaglutide, which is a peptide.
Which GLP-1 pill works better for weight loss?
In separate trials, the Wegovy pill 25 mg averaged about 13.6% loss at 64 weeks and Foundayo 17.2 mg about 11.2% at 72 weeks. There is no head-to-head trial.
Can you take Foundayo with food?
Yes. Foundayo can be taken once daily with or without food. The Wegovy pill must be taken on an empty stomach with up to 4 ounces of water and a 30-minute wait.
How much do GLP-1 pills cost without insurance?
In 2026, manufacturer self-pay prices were roughly $149 to $299 a month for the Wegovy pill and $149 to $349 for Foundayo, depending on dose. Check current prices with the manufacturer or pharmacy.
Are GLP-1 pills as effective as injections?
On average, no. Injectable tirzepatide and semaglutide have produced more weight loss in trials, but pills are a strong option for people who prefer not to inject.
Sources
- Lilly Medical, ATTAIN-1 results and Foundayo approved dosing (medical.lilly.com), 2026
- ABC News, FDA grants speedy approval to Eli Lilly weight-loss pill Foundayo, April 2026
- Wharton S et al., Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4), N Engl J Med, 2025
- Novo Nordisk, Prescribing Wegovy (NovoMedLink), 2026
- Wegovy and Foundayo U.S. prescribing information
Medical disclaimer: Pep Guide is for educational purposes only. It is not medical advice, diagnosis or treatment. Research changes over time. Talk to a licensed healthcare provider before starting, stopping or changing any medication or compound.